title: Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
authors.forename: P A
authors.initials: PA
authors.lastname: Vasey
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D019772:Topotecan / Q000008:administration & dosage
chemical_list: D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D000077146:Irinotecan; D019772:Topotecan; D002166:Camptothecin